Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.
OBJECTIVE The purpose of this study was to identify genetic variants underlying the considerable individual differences in response to antidepressant treatment . The authors performed a genome-wide association analysis of improvement of depression severity with two antidepressant drugs . METHOD High- quality Illumina Human610-quad chip genotyping data were available for 706 unrelated participants of European ancestry treated for major depression with escitalopram ( N=394 ) or nortriptyline ( N=312 ) over a 12-week period in the Genome-Based Therapeutic Drugs for Depression ( GENDEP ) project , a partially r and omized open-label pharmacogenetic trial . RESULTS Single nucleotide polymorphisms in two intergenic regions containing copy number variants on chromosomes 1 and 10 were associated with the outcome of treatment with escitalopram or nortriptyline at suggestive levels of significance and with a high posterior likelihood of true association . Drug-specific analyses revealed a genome-wide significant association between marker rs2500535 in the uronyl 2-sulphotransferase gene and response to nortriptyline . Response to escitalopram was best predicted by a marker in the interleukin-11 ( IL11 ) gene . A set of 72 a priori-selected c and i date genes did not show pharmacogenetic associations above a chance level , but an association with response to escitalopram was detected in the interleukin-6 gene , which is a close homologue of IL11 . CONCLUSIONS While limited statistical power means that a number of true associations may have been missed , these results suggest that efficacy of antidepressants may be predicted by genetic markers other than traditional c and i date s. Genome-wide studies , if properly replicated , may thus be important steps in the elucidation of the genetic basis of pharmacological response
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .